huCD7/huCD20 Mouse

The CD7 gene encodes a transmembrane glycoprotein in the immunoglobulin superfamily (IgSF). As an important co-receptor on the T cell surface, it plays a key regulatory role in T cell activation, proliferation, and signal transduction. CD7 is mainly expressed in T cells and natural killer (NK) cells, from early thymocyte development to the mature T cell stage, and also in some hematopoietic progenitor cells; however, its expression level is low in most normal non-T cell and NK cell tissues ^[1]. Abnormal expression or dysregulated signaling of CD7 is closely related to multiple diseases. As an important target for immunotherapy, CD7 has become a key molecule for targeting T-cell malignancies due to its high expression in T-cell acute lymphoblastic leukemia (T-ALL), T-cell lymphoma, and other T-cell malignant tumors ^[1]. In addition, CD7 is also associated with systemic sclerosis (SSc) and graft-versus-host disease (GvHD) ^[2-3].

Cluster of differentiation 20 (CD20), also known as MS4A1, is a functional receptor molecule on the surface of B lymphocytes, closely related to B cell activation, signal transduction, and growth regulation. CD20 is expressed at the late stage of B-cell lymphopoiesis and disappears after differentiation into plasma cells. Therefore, CD20 is expressed from pre-B cells to mature B cells, but not in plasma cells ^[4].

The huCD7/huCD20 mouse is a dual-gene humanized model obtained by crossing the huCD7 mouse (Catalog No.: C002067) with the huCD20 mouse (Catalog No.: C001625). This model can be used for studying the immune mechanisms of CD7/CD20-related malignant tumors, as well as for screening, efficacy evaluation, and safety assessment of CD7/CD20-targeted drugs.